• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Survival in Oligometastatic Prostate Cancer-A New Dawn or the Will Rogers Phenomenon?

作者信息

Connor Martin J, Winkler Mathias, Ahmed Hashim U

机构信息

Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Charing Cross Hospital, Imperial College London, London, United Kingdom.

Imperial College Healthcare Nationals Health Service Trust, Department of Urology, Charing Cross Hospital, London, United Kingdom.

出版信息

JAMA Oncol. 2020 Feb 1;6(2):185-186. doi: 10.1001/jamaoncol.2019.4724.

DOI:10.1001/jamaoncol.2019.4724
PMID:31804656
Abstract
摘要

相似文献

1
Survival in Oligometastatic Prostate Cancer-A New Dawn or the Will Rogers Phenomenon?寡转移性前列腺癌的生存——新曙光还是威尔·罗杰斯现象？
JAMA Oncol. 2020 Feb 1;6(2):185-186. doi: 10.1001/jamaoncol.2019.4724.
2
Oligometastatic Prostate Cancer: Is it Only a Matter of Perspective?寡转移前列腺癌：这仅仅是视角问题吗？
Eur Urol. 2019 May;75(5):705-706. doi: 10.1016/j.eururo.2018.12.010. Epub 2018 Dec 24.
3
Defining the Right State for a Will Rogers Phenomenon in Oligometastatic Prostate Cancer.确定寡转移前列腺癌中威尔·罗杰斯现象的正确状态。
JAMA Oncol. 2020 Jun 1;6(6):936-937. doi: 10.1001/jamaoncol.2020.0574.
4
Early prostate cancer.早期前列腺癌。
Curr Probl Cancer. 2000 Jan-Feb;24(1):5-51. doi: 10.1016/s0147-0272(00)90007-2.
5
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).镭-223 二氯化物联合立体定向消融放疗与立体定向消融放疗治疗寡转移去势抵抗性前列腺癌的随机 II 期研究（RAVENS）。
BMC Cancer. 2020 Jun 1;20(1):492. doi: 10.1186/s12885-020-07000-2.
6
[Oligometastatic prostate cancer. concept and implications.].[寡转移前列腺癌。概念及影响。]
Arch Esp Urol. 2018 Mar;71(3):239-246.
7
[Prostate cancer: increase information exchange!].[前列腺癌：加强信息交流！]
Aktuelle Urol. 2013 May;44(3):172. doi: 10.1055/s-0033-1348106. Epub 2013 May 27.
8
Risk stratification in oligometastatic prostate cancer: where are we and what do we need?寡转移前列腺癌的风险分层：我们目前的状况以及我们需要什么？
Curr Opin Urol. 2017 Nov;27(6):547-552. doi: 10.1097/MOU.0000000000000439.
9
Targeted local therapy in oligometastatic prostate cancer: a promising potential opportunity after failed primary treatment.寡转移前列腺癌的靶向局部治疗：初始治疗失败后的一个有前景的潜在机会。
BJU Int. 2015 Aug;116(2):170-2. doi: 10.1111/bju.12957. Epub 2014 Dec 30.
10
Oligometastatic prostate cancer: Reality or figment of imagination?寡转移前列腺癌：现实还是臆想？
Cancer. 2019 Feb 1;125(3):340-352. doi: 10.1002/cncr.31860. Epub 2018 Dec 6.

引用本文的文献

1
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.使用前列腺特异性膜抗原放射性配体进行前列腺癌的影像学和治疗。
Br J Radiol. 2024 Aug 1;97(1160):1391-1404. doi: 10.1093/bjr/tqae092.
2
[Local therapies for oligometastatic hormone-sensitive prostate cancer].[寡转移激素敏感性前列腺癌的局部治疗]
Urologie. 2024 Mar;63(3):215-224. doi: 10.1007/s00120-024-02280-z. Epub 2024 Feb 8.
3
Application of Advanced Imaging to Prostate Cancer Diagnosis and Management: A Narrative Review of Current Practice and Unanswered Questions.
先进成像技术在前列腺癌诊断与管理中的应用：当前实践及未解决问题的叙述性综述
J Clin Med. 2024 Jan 13;13(2):446. doi: 10.3390/jcm13020446.
4
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.去势敏感性寡转移前列腺癌的诊断与治疗：综述
Prostate Cancer Prostatic Dis. 2023 Dec;26(4):702-711. doi: 10.1038/s41391-023-00688-w. Epub 2023 Jul 8.
5
Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis.去势前列腺切除术改善寡转移患者的生存结局：一项系统的荟萃分析。
World J Surg Oncol. 2022 Aug 9;20(1):255. doi: 10.1186/s12957-022-02715-x.
6
Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer.在前列腺癌初始分期的PSMA-PET成像新时代定义寡转移疾病。
Cancers (Basel). 2022 Jul 6;14(14):3302. doi: 10.3390/cancers14143302.
7
Diagnostic Age, Age at Death and Stage Migration in Men Dying with or from Prostate Cancer in Denmark.丹麦前列腺癌死亡男性的诊断年龄、死亡年龄与分期迁移
Diagnostics (Basel). 2022 May 19;12(5):1271. doi: 10.3390/diagnostics12051271.
8
Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?根治性前列腺切除术和盆腔淋巴结清扫术后淋巴结阳性的患者——我们知道正确的处理方法吗？
Cancers (Basel). 2022 May 8;14(9):2326. doi: 10.3390/cancers14092326.
9
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.寡转移去势抵抗性前列腺癌的 C-Choline-PET/CT 识别下立体定向消融放疗（SABR）和免疫的 II 期评估。
Clin Cancer Res. 2021 Dec 1;27(23):6376-6383. doi: 10.1158/1078-0432.CCR-21-2510. Epub 2021 Sep 30.
10
Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.局部肿瘤转移前列腺癌附加治疗-新型治疗方案评估（IP2-ATLANTA）：一项多中心、二期随机对照试验的方案。
BMJ Open. 2021 Feb 25;11(2):e042953. doi: 10.1136/bmjopen-2020-042953.